About this trial
Furosemide is an old drug that has been used frequently in the postoperative period of kidney transplantation, aiming to achieve adequate urine output. There is no previous study that directly evaluate the urine response to standardized dose of furosemide in the postoperative period. The objective is to measure the urine output after standardized dose of furosemide is delivered, as a biomarker to predict the graft function in perioperative period.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Deceased donor kidney transplantation at KCMH
informed consent is accepted
Disqualifiers
Known allergy to furosemide
Surgical complication of allograft
Urgently needed for dialysis (refractory hypervolemia, uremic symptoms, and hyperkalemia)
Trial design
Single group
Treatments tested in this trial
Furosemide Injection
DrugFurosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
Treatment groups
Trial outcomes
Primary outcomes
Urine output
Urine output per hour (milliliters/hour) after furosemide injection
Secondary outcomes
Delayed graft function
Delayed graft function is defined by the necessity of dialysis within the first week after kidney transplantation. (yes/no)
Creatinine reduction ratio
Ratio of serum creatinine at postoperative day 7 and 14 to day-zero creatinine
Sponsors and contacts
Click on the lead sponsor to view all of their trials.